AIM:　To　evaluate　the　relationship　between　gene　polymorphism　(BclI,　ER22/23EK,　N363S)　and　the　occurrence,　progression　and　sensitivity　to　glucocorticoid　of　lacrimal　gland　benign　lymphoepithelial　lesion　(LGBLEL).　METHODS:　Clinical　peripheral　blood　samples　of　LGBLEL　patients　and　10　normal　volunteers　were　collected　for　DNA　extraction　and　polymerase　chain　reaction　sequencing　to　analyze　single　nucleotide　polymorphism　(SNP)　genotypes.　The　lacrimal　tissues　of　LGBLEL　were　surgically　removed　and　made　into　paraffin　sections　for　subsequent　hematoxylin-eo　sin　(HE)　and　Masson　staining　analysis.　The　duration　of　disease　and　hormone　use　of　LGBLEL　patients　from　diagnosis　to　surgery　were　also　analyzed.　Meta-analysis　follows　PRISMA　guidelines　to　conducted　a　systematic　review　of　human　studies　investigating　relationship　between　the　NR3C1　BclI　polymorphism　and　glucocorticoids　(GCs)　sensitivity.　RESULTS:　There　was　no　association　between　ER22/23EK　or　N363S　and　the　occurrence　of　LGBLEL　or　GCs　sensitivity　(P＞0.05);　BclI　GC　genotype　was　closely　related　to　GCs　resistance　(P=0.03)　as　is　the　minor　allele　C　(P=0.0017).　The　HE　staining　and　Masson　staining　showed　that　the　GC　genotype　of　BclI　remarkably　slowed　down　the　disease　progression　and　reduced　fibrosis　(P＜0.05),　especially　for　GCs-dependent　patients　(P＜0.0001).　Meta-analysis　showed　that　BclI　was　not　significantly　associated　with　GCs　responsiveness.　CONCLUSION:　The　LGBLEL　patients　who　carry　the　NR3C1　BclI　allele　C　may　be　more　sensitive　to　GCs　and　associated　with　lower　fibrosis　and　slower　disease　progression.　The　results　may　guide　the　clinical　treatment　strategy　for　the　LGBLEL　patients.